COMPASS Pathways logo

COMPASS Pathways

CMPS | NASDAQ
Chart Builder DCF Calculator
$15.01
-$0.18 (-1.18%)
At close: Sep 21, 2026, 4:00 PM ET
$15.05
+$0.04 (+0.27%)
Pre-market: Sep 22, 2026, 5:40 AM ET
-1.18%

Rating

Updated: Aug 29, 2026
19.7
Fundamentals Weak
Market Sentiment Neutral
Moat None

Key Statistics

Market Data

Market Cap $2.03B
1D Range
14.88 15.55
52W Range
4.82 15.87

Valuation (TTM)

PE -2.69
PB 23.96
EV/EBITDA -4.20

Valuation (NTM)

Forward PE N/A
Forward PEG 0.10
Price Target $18.63
Loading financial charts...

Profile

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on develo...

Sector Healthcare
Industry Biotechnology
Employees 156
IPO Date Sep 17, 2020
Fiscal Year January - December

Latest News

COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

4 days ago · seekingalpha.com

COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

5 days ago · seekingalpha.com

COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

2 months ago · seekingalpha.com

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript
Compass Pathways (CMPS) to Post Quarterly Earnings on Thursday

2 months ago · defenseworld.net

Compass Pathways (CMPS) to Post Quarterly Earnings on Thursday
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

3 months ago · seekingalpha.com

COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$18
Upside
+19.92%
Buy (10)
Hold (0)
Sell (0)
Analyst Details

© 2026 bestshares.com. All rights reserved.